Indonesian Journal of Obstetrics and Gynecology (Jan 2018)

The Effect of Cyclophosphamide Chemotherapy on Ovarian AntiMüllerian Hormone Levels in Breast Cancer Patients

  • Elisabeth G.K. Liga,
  • Nusratuddin Abdullah,
  • Eddy Tiro,
  • St. Maisuri T. Chalid

DOI
https://doi.org/10.32771/inajog.v6i1.761

Abstract

Read online

Objective: To evaluate cyclophosphamide effects on Anti- Müllerian hormone (AMH) levels in breast cancer patients treated with cyclophosphamide chemotherapy. Methods: This cohort prospective study was conducted in Dr. Wahidin Sudirohusodo Hospital in the Department of Obstetrics and Gynecology in collaboration with Department of Surgery, Faculty of Medicice, Universitas Hasanuddin between September 2015 and June 2016. Serum levels of AMH from forty breast cancer patients received three series of cyclophosphamide chemotherapy determined by Enzyme Linked Immuno Sorbent Assay (ELISA). Results: Serum AMH levels decreased significant in the first series (from 2.092.04 g/ml to o.651.06 g/ml; p<0.05) through the third series (from 1.531.34 g/ml to 0.50.65 g/ml; p<0.05) of cyclophosphamide chemotherapy. Conclusion: AMH levels decreased significant after cyclophosphamide indicated that cyclosphosphamide decrease ovarian reserve. [Indones J Obstet Gynecol 2018; 6-1: 64-67] Keywords: anti-müllerian hormone, breast cancer, cyclophosphamide, ovarian reserveObjective: To evaluate cyclophosphamide effects on Anti- Müllerian hormone (AMH) levels in breast cancer patients treated with cyclophosphamide chemotherapy. Methods: This cohort prospective study was conducted in Dr. Wahidin Sudirohusodo Hospital in the Department of Obstetrics and Gynecology in collaboration with Department of Surgery, Faculty of Medicice, Universitas Hasanuddin between September 2015 and June 2016. Serum levels of AMH from forty breast cancer patients received three series of cyclophosphamide chemotherapy determined by Enzyme Linked Immuno Sorbent Assay (ELISA). Results: Serum AMH levels decreased significant in the first series (from 2.092.04 g/ml to o.651.06 g/ml; p<0.05) through the third series (from 1.531.34 g/ml to 0.50.65 g/ml; p<0.05) of cyclophosphamide chemotherapy. Conclusion: AMH levels decreased significant after cyclophosphamide indicated that cyclosphosphamide decrease ovarian reserve. Keywords: anti-müllerian hormone, breast cancer, cyclophosphamide, ovarian reserve